Background Chromogenic in situ hybridization (CISH) is fast becoming a well established technique for easy and sensitive determination of HER2 gene status in breast cancer. However, for the ...

The PFS benefit with T-DXd was observed across all prespecified patient subgroups. Overall survival (OS) data were not mature ...

What they found was that: A breast biopsy is used to determine HER2 status. The biopsy can be sent for laboratory testing with an immunohistochemistry test. The fluorescence in situ hybridization ...

Enhertu (fam-trastuzumab deruxtecan-nxki) is currently indicated as a second-line therapy for HER2-positive metastatic breast cancer.

During a live event, Megan Kruse, MD, discussed NCCN guidelines and key therapies for patients with HR-positive metastatic ...

This core performs non-radioactive, RNA in situ hybridization (ISH) on tissue sections. A unique high-throughput technology developed by the core (Yaylaoglu MB, Titmus A, Visel A, Alvarez-Bolado G, ...

is approved in more than 75 countries worldwide for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization (ISH ...

Not significant different from CISH HER2 signals in a two tailed, paired t-test (N = 348, P = 0.245) d) Not significant different from CISH HER2 signals in a two-tailed, paired t-test (N = 350 ...

Precision Cancer Pathology group performs RNA in situ hybridization for formalin fixed paraffin embedded tissue sections, fixed cultured cells and fixed/frozen tissue sections. We use either ...